Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses

NCT: NCT03265366 · COMPLETED

NCT IDNCT03265366
StatusCOMPLETED
Start Date2017-09-14
Completion2020-01-24

Brief Summary

The aim of the study is to compare the concordance between chest computerized tomography-scan (CTscan) and Magnetic resonance Imaging (MRI) for the description of the abnormalities seen in Allergic BronchoPulmonary Aspergillosis (ABPA).

Frequently Asked Questions

What is Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses?

Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses is a clinical trial registered under NCT03265366. Current status: COMPLETED.

What is the status of NCT03265366?

The current status of NCT03265366 (Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses) is: COMPLETED.

When did Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses start?

Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses started on 2017-09-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑